Elucid Bioimaging is pleased to announce that they have met their recruiting targets for the Q-CAMP studyFebruary 22, 2017
Wenham, MA–(BUSINESS WIRE)
Elucid Bioimaging is pleased to announce that they have met their recruiting targets for the Q-CAMP study, enrollment has been completed and preliminary results will be announced in early June. Elucid started the Non-invasive Computer-Aided Phenotyping of Vasculopathy (Q-CAMP) study in 2014. Q-CAMP is a cross-sectional study of patients undergoing endarterectomy of the carotid or femoral arteries. The purpose of the study is to validate Elucid’s vascuCAP software measurements of plaque components from CT angiography and multi-sequence MR versus the histopathologic examination of vascular tissue removed during endarterectomy. Multiple cross-sections of the excised plaque lesions are analyzed by pathologists to identify sub-regions of calcification, lipid rich necrotic core and fibrotic components which are then compared the strata of components mapped by vascuCAP from pre-surgical image data.
Andrew Buckler, Founder and CTO of Elucid said: “We are excited to complete and publish the analysis results. We believe that vascuCAP measurement and mapping of the calcified, fibrotic and lipid-rich regions of plaque, once approved for clinical use, may have a significantly greater impact on clinical care than calcium scoring and stenosis grading by themselves. ”
“This is a unique study combining advanced imaging and pathology,” said Dr. Malachi Sheahan, principal investigator and Program Director for Vascular Surgery at Louisiana State University, “I think that characterization of plaque components from imaging, validated by pathology, holds great potential to improve decision making for better safety and outcomes in this space.”
About Elucid Bioimaging
Elucid, based in Wenham, MA, specializes in advanced imaging technology for the development of new therapies and imaging companion diagnostics.
More information about Q-CAMP is available on clinicaltgrials.gov